← USMLE Vault · Free Guides usmlevault.com →

First Aid for the USMLE Step 1 · 2026 edition

367 changes. We went through the book page by page.

Every addition, rewrite and deletion between the 2025 and 2026 editions, flagged and mapped to its page number. Below is a sample — four or five per system. The full set lives in the Vault.

367Total changes
160New content
100Rewritten
23Deleted
84Page shifts
5Corrections
Open the full change list Filter by system, page and yield at usmlevault.com
AddedContent that did not exist in 2025.
RewrittenSame topic, changed wording or mechanism.
CorrectionFA 2025 was factually wrong. Overwrite it.

Biochemistry

First Aid pp. 34–92

33changes
16 added14 rewritten3 cut1 correction
69page
FA 2025 correction

Kwashiorkor

CRITICAL FACTUAL CORRECTION — Kwashiorkor ADH direction changed from decreased to increased

2025

decreased plasma oncotic pressure (arising from decreased serum albumin and decreased antidiuretic hormone)

2026

decreased plasma oncotic pressure (arising from decreased serum albumin and increased antidiuretic hormone)

Why it matters

FA 2025 was wrong. If you memorized kwashiorkor → decreased ADH, overwrite it now — any Anki card or MCQ explanation citing decreased ADH is outdated and will mislead you on a fluid-balance vignette.

34page
Rewritten

Purine Synthesis Drug Targets

6-MP mechanism rewritten — 6-TGN pathway explicit, allopurinol interaction and CBC monitoring added

2025

6-Mercaptopurine (6-MP) and its prodrug azathioprine block purine synthesis. Azathioprine is used for immunosuppression after transplants and in autoimmune disease.

2026

6-Mercaptopurine (6-MP) and its prodrug azathioprine block purine synthesis. 6-MP has an immunosuppressive effect via conversion of 6-MP to 6-thioguanine nucleotides (6-TGNs). Concurrent use of xanthine oxidase inhibitors (eg, allopurinol) increases 6-MP conversion, increases 6-TGN levels (toxic), increases risk of severe immunosuppression; reduce dose and monitor CBC.

Why it matters

Allopurinol + 6-MP is a classic drug interaction vignette. Now testable as a two-step mechanism question: why does allopurinol increase toxicity? Because it shunts more 6-MP toward 6-TGN conversion.

37page
Added

Base Excision Repair

BER now specified as handling oxidative stress, radiation, alkylating agents, replication errors

2026

Important in repair of damage via oxidative stress, radiation, alkylating agents, or replication errors.

Why it matters

BER damage types are now explicitly testable. The differentiator from NER is lesion size: BER = single damaged base; NER = bulky helix-distorting lesion. Expect a vignette with oxidative damage + glycosylase.

44page
Rewritten

Growth Factors / Cell Cycle

EPO now classified as nonreceptor tyrosine kinase via JAK2 — distinct from receptor TKs

2025

Growth factors (eg, insulin, PDGF, EPO, EGF) bind tyrosine kinase receptors to transition the cell from G1 to S phase.

2026

Growth factors bind receptor (eg, insulin, PDGF, EGF) and nonreceptor (eg, EPO via JAK2) tyrosine kinases to transition the cell from G1 to S phase.

Why it matters

EPO is now explicitly nonreceptor TK — JAK2 docks on externally. Expect a vignette where EPO/JAK2 mutation (polycythemia vera) is the trap for receptor TK answer choices.

46page
Rewritten

Zellweger Syndrome

Zellweger accumulation corrected — VLCFA added, location is plasma and urine not peroxisomes

2025

Zellweger syndrome: accumulation of pipecolic acid in peroxisomes

2026

Zellweger syndrome: accumulation of VLCFA and pipecolic acid in plasma and urine

Why it matters

Two corrections in one: VLCFA is the key diagnostic lab finding (not just pipecolic acid), and the accumulation is in plasma/urine (measurable), not trapped in peroxisomes.

+28 more Biochemistry changes — mapped page by page inside the Vault usmlevault.com →

Immunology

First Aid pp. 96–115

23changes
13 added8 rewritten1 cut1 moved
98page
Added

MHC / Bare Lymphocyte Syndrome

Entirely new immunodeficiency disease added to FA 2026

2026

Bare lymphocyte syndrome: Autosomal recessive. Decreased MHC expression leads to T-cell dysfunction. Type I: TAP mutation causes decreased MHC I leading to decreased CD8+ T cells and chronic sinopulmonary infections. Type II: defective MHC II transcription factors cause decreased MHC II leading to decreased CD4+ T cells and susceptibility to intracellular pathogens.

Why it matters

Brand new immunodeficiency = guaranteed test fodder within 2 cycles. Type I vs Type II distinction (CD8 vs CD4 deficiency) is a perfect two-step vignette. Flow cytometry showing absent HLA-DR is the pathognomonic finding.

101page
Added

Peripheral Tolerance

New concept — peripheral tolerance distinguishing from central tolerance

2026

Peripheral tolerance: Suppression/inactivation of self-reactive T/B cells (outside thymus/bone marrow) preserves self-tolerance; loss leads to autoimmunity. Mechanisms include: anergy (lack of co-stimulation), regulatory T cells (Tregs), and clonal deletion.

Why it matters

Peripheral vs central tolerance is now explicitly separated — expect a vignette asking which mechanism fails when autoimmunity develops despite intact thymic selection. Anergy (no co-stimulation) is the most testable mechanism.

105page
Added

Complement Pathway Testing

New diagnostic framework for complement pathway testing

2026

Complement pathway testing: CH50 (total hemolytic complement) tests classical pathway. Low CH50 + low C3 indicates alternative/classical pathway consumption. Low CH50 + normal C3 indicates terminal complement deficiency. C4 level distinguishes classical from alternative pathway defects.

Why it matters

Complement lab interpretation is now explicitly testable. CH50 + C3 + C4 pattern recognition is a classic NBME framework: low CH50 with normal C3 = terminal deficiency, low CH50 with low C3 = consumption. Expect a lab-values vignette.

109page
Rewritten

Vaccine Types, Conjugate Vaccines

Mechanism emphasis shifted from brand names to carrier protein conjugation principle

2025

Examples listed as PCV13, PCV15, and PCV20 polysaccharide

2026

A polysaccharide conjugated to a carrier protein — converts T-independent antigen to T-dependent; enhances immunogenicity in children <2 years

Why it matters

The teaching point shifted from memorizing brand names to understanding the mechanism. Expect: why do polysaccharide vaccines fail in infants? Answer: T-independent response (no memory, no class switching). Carrier protein conjugation fixes this.

111page
Added

Type IV Hypersensitivity, AGEP

AGEP added as new SCARs entity — distinct from DRESS

2025

DRESS (Drug reaction with eosinophilia and systemic symptoms)

2026

Drug reactions — severe cutaneous adverse reactions (SCARs): acute generalized exanthematous pustulosis (AGEP) — widespread sterile pustules on erythematous base, fever, leukocytosis with eosinophilia. Caused by antibiotics (amoxicillin, ampicillin), antimalarials, Ca2+ channel blockers. Resolves within 2 weeks of stopping drug. Type IV hypersensitivity.

Why it matters

AGEP is a brand new SCARs entity in FA 2026. Key differentiators from DRESS: sterile pustules (not morbilliform rash), mucosal sparing, shorter onset, self-limited. From SJS/TEN: no epidermal necrosis, no Nikolsky sign. Expect a derm vignette with pustules after amoxicillin.

+18 more Immunology changes — mapped page by page inside the Vault usmlevault.com →

Microbiology

First Aid pp. 126–200

14changes
5 added1 rewritten1 cut7 moved
168page
Added

Dengue Virus, Diagnosis Column

Diagnostic methods explicitly added to dengue entry — NAAT for early infection, serology for later

2025

Dengue virus diagnosis column — no specific diagnostic tests listed

2026

Dengue virus diagnosis: NAAT (nucleic acid amplification testing) — used in early infection (days 1-5, before antibody seroconversion); serology (IgM/IgG) — used after day 5 when antibodies have developed

Why it matters

Brand-new testable content. NBME loves timing-based diagnostic questions. Know: NAAT = days 1-5 (viremia present, no antibodies yet); serology = day 5+ (antibodies rising, viremia falling). This distinction is now fair game.

200page
Added

Hepatitis C Therapy, NS5A Inhibitors

NS5A inhibitor mechanism expanded — two new functions added

2025

NS5A inhibitors: key role in RNA replication

2026

NS5A inhibitors: key role in RNA replication, virion assembly, and release

Why it matters

FA 2026 expands NS5A from one function to three. Expect mechanism-of-action questions distinguishing NS5A inhibitors (replication + assembly + release) from NS5B inhibitors (RNA synthesis only). This is new testable content.

+12 more Microbiology changes — mapped page by page inside the Vault usmlevault.com →

General Pathology

First Aid pp. 202–225

18changes
9 added8 rewritten1 cut
202page
Rewritten

Cellular Adaptations, Metaplasia

Barrett esophagus now explicitly named as the canonical metaplasia example

2025

Metaplasia — usually due to exposure to an irritant, with generic examples

2026

Metaplasia example clarified: esophageal exposure to gastric acid (GERD) → replacement of stratified squamous epithelium with columnar epithelium (Barrett esophagus). This is squamous-to-columnar metaplasia driven by chronic acid irritation.

Why it matters

Barrett esophagus is the single most tested metaplasia example on NBME. Having it named explicitly means vignettes describing chronic GERD with biopsy showing columnar epithelium now map directly to this page.

203page
Added

Cell Injury / Cell Death, Ferroptosis

Entirely new cell death mechanism added to FA 2026

2026

Ferroptosis: Iron-dependent, regulated form of cell death. Characterized by accumulation of lipid peroxides. Regulated by glutathione peroxidase 4 (GPX4), which normally neutralizes lipid peroxides. GPX4 inactivation → lipid peroxide accumulation → ferroptosis. Distinct from apoptosis (no caspases), necrosis (not accidental), and pyroptosis (no inflammasome).

Why it matters

Brand new testable concept. Expect vignettes showing cell death rescued by iron chelators and vitamin E but NOT by caspase inhibitors. The distinguishing feature is iron-dependence + lipid peroxides + no caspase involvement.

210page
Added

Acute Inflammation, Inflammasome Expansion

Inflammasome entry expanded with DAMPs/PAMPs activation, pyroptosis role, and NLRP3 as canonical example

2026

Inflammasome expanded: activated by DAMPs/PAMPs, role in pyroptosis, and NLRP3 identified as the canonical inflammasome example. Cytoplasmic complex that activates caspase-1 → cleavage of pro-IL-1β → active IL-1β.

Why it matters

NLRP3 is now explicitly named — expect it as a correct answer in vignettes about gout (urate crystals = DAMP activating NLRP3) or familial Mediterranean fever. Pyroptosis link means inflammasome questions can now cross-reference cell death pathways.

217page
Added

Warburg Effect, Mechanism

PKM2 named as enzymatic driver of Warburg effect

2026

Warburg effect: driven by altered metabolic enzymes (eg, pyruvate kinase isoform PKM2) that favor aerobic glycolysis over oxidative phosphorylation.

Why it matters

PKM2 is a new testable enzyme. Vignettes about cancer metabolism can now ask which enzyme isoform creates the metabolic bottleneck that enables biosynthetic precursor accumulation in rapidly dividing cells.

217page
Rewritten

Warburg Effect, Function

Core rationale reframed — biosynthetic precursors, not ATP, are the primary benefit

2025

Aerobic glycolysis provides rapidly dividing cancer cells with ATP despite being less efficient

2026

Aerobic glycolysis supplies rapidly dividing cancer cells with biosynthetic precursors (eg, nucleotides, amino acids, lipids) needed for rapid proliferation — energy production is secondary to anabolic substrate supply.

Why it matters

The old 'inefficient ATP' framing is now wrong. If a vignette asks WHY cancer cells use aerobic glycolysis, the answer is biosynthetic precursors for cell division — not energy. ATP as the answer is now the trap.

+13 more General Pathology changes — mapped page by page inside the Vault usmlevault.com →
All 367 changes — every one tied to its First Aid page, filterable by system and yield. Open the full list at usmlevault.com →

General Pharmacology

First Aid pp. 228–251

14changes
6 added6 rewritten2 moved
228page
Rewritten

Pharmacodynamics: Graded Dose Response — EC50

EC50 definition expanded with Emax clarifier and potency statement

2025

EC50: Drug concentration that produces 50% of maximal effect

2026

EC50: Concentration of drug that produces 50% of maximal effect (Emax). Lower EC50 → greater potency

Why it matters

NBME loves asking which drug is more potent on a dose-response curve. The explicit 'Lower EC50 = greater potency' rule lets you answer without memorizing individual drug values — just compare leftward shifts.

239page
Added

Cholinomimetic Agents: Pilocarpine

Sjogren syndrome added as pilocarpine clinical use

2025

Pilocarpine: used for glaucoma, xerostomia

2026

Pilocarpine: used for glaucoma, xerostomia, Sjogren syndrome

Why it matters

Sjogren syndrome + xerostomia + muscarinic agonist is a complete vignette in three words. This is a gimme question if you link pilocarpine to Sjogren — expect it on your exam.

240page
Rewritten

Anticholinergic Agents: Floppy Iris Syndrome

Floppy iris syndrome expanded with mechanism and clinical presentation

2025

Floppy iris syndrome (brief mention)

2026

Floppy iris syndrome: intraoperative complication; iris billows and prolapses during cataract surgery, caused by alpha-1 blocker use (e.g., tamsulosin)

Why it matters

Tamsulosin (BPH drug) + cataract surgery = floppy iris. This is a two-step vignette: elderly man on tamsulosin undergoes eye surgery, iris prolapses. The mechanism is alpha-1 blockade of iris dilator muscle.

248page
Rewritten

Lead Poisoning Findings

Drops clarified as radial nerve palsy (wrist drop) and peroneal nerve palsy (foot drop)

2025

Encephalopathy, Erythrocyte stippling, Abdominal colic, Drops (wrist and foot)

2026

Encephalopathy, Erythrocyte stippling, Abdominal colic, Drops (radial nerve palsy)

Why it matters

NBME won't say 'wrist drop' — they'll describe inability to extend the wrist and ask which nerve is affected. Knowing it's radial nerve palsy (not just 'drop') gives you the answer directly.

251page
Added

Hepatically Cleared Drugs: Warfarin

Warfarin added to hepatically cleared drugs list with CYP450 interaction note

2026

Warfarin: hepatic metabolism via CYP450 enzymes (primarily CYP2C9, also CYP3A4 and CYP1A2), narrow therapeutic index, many drug interactions

Why it matters

Warfarin + CYP inducer/inhibitor drug interactions are tested every single exam. Having it explicitly listed under hepatically cleared drugs reinforces why rifampin decreases and azoles increase its effect.

+9 more General Pharmacology changes — mapped page by page inside the Vault usmlevault.com →

Public Health Sciences

First Aid pp. 256–278

35changes
6 added4 rewritten3 cut22 moved
256page
Added

Twin Concordance Study

Added schizophrenia example for twin concordance

2026

Example: If one MZ twin develops schizophrenia, the other twin has ~50% concordance (not 100%) — demonstrates genetic contribution but not genetic determinism.

Why it matters

Classic Step 1 crossover between genetics and psychiatry. The 50% figure is directly testable — expect vignettes asking what MZ concordance <100% implies about heritability.

256page
Added

Adoption Study

Added schizophrenia example for adoption studies

2026

Example: Adopted child has higher schizophrenia risk if biological parents have schizophrenia (not adoptive parents) — demonstrates genetic over environmental contribution.

Why it matters

Pairs with twin concordance to reinforce genetics vs environment distinction. Expect vignettes where biological parent history is the key variable separating answer choices.

260page
Added

Hazard Ratio (New Topic)

Brand new topic: Hazard ratio added to biostatistics

2026

Hazard ratio (HR): Ratio of hazard rates between two groups. Interpreted like relative risk in survival analysis. HR >1 = increased risk of event. HR <1 = decreased risk. Used in time-to-event analyses (Kaplan-Meier, Cox proportional hazards regression). Unlike RR, HR accounts for censoring and varying follow-up times.

Why it matters

Brand new testable content. NBME biostat questions now require distinguishing HR from RR and OR. HR = instantaneous rate ratio in survival analysis; RR = cumulative incidence ratio in cohorts.

264page
Rewritten

Null Hypothesis

Null hypothesis definition broadened from disease-specific to general

2025

Null hypothesis (H0): zero association between disease and risk factor

2026

Null hypothesis (H0): zero difference between two groups or variables

Why it matters

Definition now applies to ANY hypothesis test — means, proportions, correlations, regressions. Expect vignettes framing H0 in non-disease contexts (e.g., comparing two teaching methods).

264page
Rewritten

Alternative Hypothesis

Alternative hypothesis definition broadened

2025

Alternative hypothesis (H1): at least one difference or relationship

2026

Alternative hypothesis (H1): at least one difference or association between groups or variables

Why it matters

Paired with null hypothesis update. The broader framing means H1 questions can now use 'association' language instead of strictly 'relationship' — same concept, wider application.

+30 more Public Health Sciences changes — mapped page by page inside the Vault usmlevault.com →

Cardiovascular

First Aid pp. 284–325

52changes
9 added8 rewritten1 cut34 moved
285page
Rewritten

AV Septal Defect Mechanism

AV septal defect description updated from classification to mechanism

2025

acyanotic congenital heart disease

2026

incomplete fusion of endocardial cushions

Why it matters

Endocardial cushion defects are heavily tested. Knowing the mechanism (incomplete fusion) connects AV septal defects to Down syndrome and links embryology to pathology.

308page
Added

Sudden Cardiac Death

Definition of sudden cardiac death added

2026

Sudden cardiac death: unexpected death from cardiac arrhythmia within 1 hour of symptom onset.

Why it matters

Sudden cardiac death is defined by the 1-hour window. Boards test this definition to distinguish it from other causes of unexpected death (PE, aortic dissection).

309page
Rewritten

CK-MB Timing

CK-MB rise time updated from 6-12 hours to 4-6 hours with full kinetics

2025

CK-MB rises at 6–12 hours

2026

CK-MB rises at 4–6 hours, peaks at 24 hours, returns to baseline in 72 hours

Why it matters

Biomarker timing is a perennial board favorite. CK-MB now rises earlier (4-6 hr) and its fast baseline return (72 hr) makes it useful for detecting reinfarction.

311page
Added

Atrial Fibrillation Management

Pulse field ablation added as emerging rhythm control technique for AFib

2026

Atrial fibrillation rhythm control options: cardioversion, catheter ablation, or pulse field ablation (emerging technique). Pulse field ablation uses brief high-voltage electrical pulses to create irreversible electroporation of cardiac tissue; tissue-selective (targets myocardium while sparing esophagus and phrenic nerve).

Why it matters

Pulse field ablation is the newest AFib intervention in FA 2026. Its tissue selectivity (spares esophagus/phrenic nerve) is the key distinguishing feature from thermal ablation.

315page
Added

Dilated Cardiomyopathy TTN Mutation

TTN gene mutation identified as most common genetic cause of familial DCM

2026

TTN mutation → shortened titin protein. Most common genetic cause of familial DCM (~25% of familial cases). Titin spans half the sarcomere (Z-disc to M-line); truncating mutations impair sarcomere assembly → systolic dysfunction → chamber dilation.

Why it matters

TTN is now THE named genetic cause of familial DCM. Expect vignettes: young patient + family history of heart failure + dilated LV = TTN mutation. Genetics meets cardiology.

+47 more Cardiovascular changes — mapped page by page inside the Vault usmlevault.com →

Endocrine

First Aid pp. 330–342

13changes
7 added4 rewritten2 cut
330page
Added

Somatostatin Alternate Name

Somatostatin alternate name SRIF added

2025

Somatostatin: GHIH (growth hormone release inhibiting hormone)

2026

Somatostatin: GHIH (growth hormone release inhibiting hormone). Also called somatotropin release inhibiting factor (SRIF).

Why it matters

SRIF is an alternate name that can appear in NBME stems. Knowing both names prevents you from picking a wrong answer when the question uses the less common terminology.

334page
Added

SIADH Diagnosis

Euvolemia added as explicit diagnostic criterion for SIADH

2025

Diagnosis: Uosm > Posm

2026

Diagnosis: Uosm > Posm, euvolemia

Why it matters

Euvolemia is what distinguishes SIADH from hypervolemic hyponatremia (CHF, cirrhosis) and hypovolemic causes. Expect vignettes describing a euvolemic patient to cue SIADH as the diagnosis.

338page
Added

Medullary Thyroid Carcinoma Tumor Markers

CEA added as tumor marker alongside calcitonin for medullary thyroid CA

2025

Parafollicular C cells produce calcitonin.

2026

Parafollicular C cells produce calcitonin. Both calcitonin and CEA (carcinoembryonic antigen) are used as tumor markers for post-operative surveillance.

Why it matters

The calcitonin + CEA combination is now explicitly testable. A post-thyroidectomy surveillance question for MTC should trigger you to pick both markers — not thyroglobulin (that's papillary/follicular).

341page
Added

MEN 1 Manifestations

GHRH-secreting hypothalamic tumor added to MEN 1

2025

MEN 1: 3 P's (Pituitary, Pancreas, Parathyroid)

2026

MEN 1: 3 P's (Pituitary, Pancreas, Parathyroid). Also includes GHRH-secreting hypothalamic tumors.

Why it matters

A MEN 1 patient with acromegaly features may have a GHRH-secreting hypothalamic tumor rather than a primary pituitary adenoma. The treatment target differs — hypothalamic source vs pituitary.

342page
Rewritten

Carcinoid Syndrome Cardiac Manifestations

Carcinoid cardiac manifestation reframed from valvular disease to right heart failure

2025

Flushing, Diarrhea, Right-sided valvular disease (Tricuspid regurgitation and pulmonary stenosis)

2026

Flushing, Diarrhea, Right heart failure (from right-sided valvular lesions: tricuspid regurgitation and pulmonary stenosis)

Why it matters

The testable endpoint is now right heart failure, not just valvular disease. If asked about the cardiac complication of carcinoid, pick right heart failure. Left valves are spared because serotonin is metabolized in the lungs.

+8 more Endocrine changes — mapped page by page inside the Vault usmlevault.com →
160 topics are new this year. Each one is written up in the Vault with a practice question attached. See what’s new at usmlevault.com →

Gastrointestinal

First Aid pp. 364–398

21changes
11 added8 rewritten1 cut1 moved1 correction
364page
FA 2025 correction

Tongue Development

Tongue anterior 2/3 origin corrected — now includes both 1st and 2nd pharyngeal arches

2025

The anterior two-thirds of the tongue is derived from the 1st pharyngeal arch.

2026

The anterior two-thirds of the tongue is formed by portions of BOTH the 1st and 2nd pharyngeal arches. The lateral lingual swellings arise from the 1st arch, while the tuberculum impar (median tongue bud) receives contributions from both the 1st and 2nd arches.

Why it matters

This is a factual correction from FA 2025. Previous editions said 1st arch only. Expect NBME questions testing pharyngeal arch contributions to tongue development — the old answer (1st arch only) is now wrong.

367page
Added

Pancreas Divisum

Pancreas divisum drainage pattern specified — dorsal duct to minor papilla (dominant), ventral to major papilla

2026

In pancreas divisum, the dorsal pancreatic duct (of Santorini) drains the majority of the pancreas through the minor papilla (dominant drainage), while the ventral duct (of Wirsung) drains only the uncinate process and inferior head through the major papilla. The minor papilla provides relatively inadequate drainage for the dominant dorsal duct, predisposing to recurrent pancreatitis.

Why it matters

NBME loves anatomy-based pancreatitis questions. The key testable point: dorsal duct is dominant but drains through the smaller minor papilla — that mismatch causes obstruction and recurrent pancreatitis.

387page
Rewritten

Ulcer Hemorrhage Artery Mapping

Ulcer bleeding expanded from single artery to location-specific mapping

2025

Ruptured gastric ulcer on lesser curvature → left gastric artery.

2026

Ulcer hemorrhage artery mapping: Lesser curvature of stomach → left gastric artery. Posterior duodenal bulb → gastroduodenal artery. Posterior stomach (body/fundus) → splenic artery.

Why it matters

NBME tests specific ulcer location-to-artery pairings. The classic high-yield association: posterior duodenal ulcer erodes into the gastroduodenal artery causing massive hemorrhage. Know all three mappings.

388page
Added

Celiac Disease + IgA Deficiency

IgG-based testing preferred when selective IgA deficiency present

2026

In selective IgA deficiency, IgA-based celiac serologies (anti-tTG IgA, anti-endomysial IgA) will be falsely negative. Use IgG-based testing: IgG anti-tTG or IgG deamidated gliadin peptide (DGP) antibodies.

Why it matters

Selective IgA deficiency is 10-15x more common in celiac patients. If a vignette shows negative IgA anti-tTG with undetectable serum IgA, the next step is IgG-based testing — not repeat testing or biopsy.

395page
Added

Lynch Syndrome Associated Malignancies

Stomach cancer added to Lynch syndrome-associated malignancies

2026

Lynch syndrome (HNPCC) associated malignancies now include stomach cancer. Updated list: Colorectal, Endometrial, Ovarian, Small bowel, Stomach.

Why it matters

Stomach cancer is no longer a valid distractor for 'which cancer is NOT associated with Lynch syndrome' questions. The association list expanded — memorize the updated CEOSS mnemonic.

+16 more Gastrointestinal changes — mapped page by page inside the Vault usmlevault.com →

Hematology & Oncology

First Aid pp. 425–446

21changes
10 added7 rewritten3 cut1 moved1 correction
428page
FA 2025 correction

Sickle Cell Hb Electrophoresis

HbA is ABSENT in HbSS, not just decreased — factual correction

2025

Hb electrophoresis shows decreased HbA

2026

Hb electrophoresis shows absent HbA

Why it matters

In homozygous HbSS, both beta-globin genes carry the sickle mutation so NO normal HbA is produced. Pattern: HbS ~90%, HbF variable, HbA2 ~2-3%, HbA = 0%. This distinguishes from sickle trait (HbAS) where HbA is ~55-60%.

425page
Added

Beta-Thalassemia Gene Therapy

Gene therapy added as curative option for severe beta-thalassemia

2026

For severe beta-thalassemia (transfusion-dependent), gene therapy via beta-globin gene addition or gene editing can restore functional beta-globin production. This represents a curative option, potentially eliminating lifelong transfusion dependence. Exagamglogene autotemcel (exa-cel) uses CRISPR-Cas9 to edit BCL11A enhancer, reactivating fetal hemoglobin. Betibeglogene autotemcel (beti-cel) adds functional beta-globin gene via lentiviral vector.

Why it matters

Gene therapy for beta-thal is now testable. Know the two approaches: CRISPR editing BCL11A (reactivates HbF) vs lentiviral beta-globin addition. Both are curative for transfusion-dependent disease.

432page
Added

HUS Pathophysiology

HUS mechanism now explicitly stated: endothelial dysfunction → capillary microthrombi → renal vascular occlusion

2026

Shiga toxin (from EHEC O157:H7) causes: (1) Endothelial dysfunction — direct toxicity to glomerular endothelial cells, (2) Capillary microthrombi — platelet consumption at damaged endothelium, (3) Renal vascular occlusion — mechanical obstruction of glomerular capillaries. This produces the classic triad: thrombocytopenia + MAHA + acute renal failure. Key distinction from TTP: HUS = primary endothelial injury (toxin-mediated). TTP = ADAMTS13 deficiency leading to uncleaved vWF multimers.

Why it matters

HUS vs TTP mechanism is a high-yield vignette differentiator. HUS = Shiga toxin damages endothelium directly. TTP = ADAMTS13 deficiency. Both cause MAHA + thrombocytopenia but the WHY is completely different.

437page
Added

AML t(15;17) PML-RARalpha

PML-RARalpha fusion protein mechanism now explicitly named for APL

2026

The t(15;17) translocation in acute promyelocytic leukemia (APL) produces the PML-RARalpha fusion protein. This fusion protein blocks myeloid differentiation at the promyelocyte stage by repressing retinoic acid-responsive genes. All-trans retinoic acid (ATRA) overcomes the block by binding RARalpha at pharmacologic doses, forcing differentiation of promyelocytes into mature granulocytes.

Why it matters

PML-RARalpha is now explicitly named — expect it as an answer choice. The mechanism (blocks differentiation → ATRA forces differentiation) is a two-step question: what does the fusion do, and how does ATRA fix it.

438page
Added

Oncogenic Signaling Pathways in Hematologic Malignancies

New topic — oncogenic pathways table linking mutations to malignancies and targeted therapies

2026

Oncogenic signaling pathways in hematologic malignancies: BCR-ABL t(9;22) — constitutive tyrosine kinase — CML, Ph+ ALL — imatinib, dasatinib. JAK2 V617F — JAK-STAT signaling — polycythemia vera, essential thrombocythemia, primary myelofibrosis — ruxolitinib. FLT3-ITD — receptor tyrosine kinase — AML (poor prognosis) — midostaurin, gilteritinib. NPM1 — nucleolar protein shuttling — AML (favorable prognosis) — standard chemo (good response). Key concept: these represent gain-of-function mutations that drive proliferation independent of normal growth signals.

Why it matters

This table is extremely high-yield. Memorize mutation-malignancy-drug triplets: BCR-ABL/CML/imatinib, JAK2/PV/ruxolitinib, FLT3/AML-poor/midostaurin. Expect a vignette asking which molecular abnormality drives a given presentation.

+16 more Hematology & Oncology changes — mapped page by page inside the Vault usmlevault.com →

Musculoskeletal & Skin

First Aid pp. 452–478

17changes
9 added6 rewritten1 cut1 moved1 correction
456page
FA 2025 correction

Sciatic Nerve Sensory Distribution

Factual correction: sciatic nerve sensory changed from posterior thigh to posterior knee

2025

Sciatic nerve provides sensory innervation to the posterior thigh.

2026

Sciatic nerve provides sensory innervation to the posterior knee (articular branches) before bifurcating into tibial and common fibular nerves.

Why it matters

Factual correction. The posterior thigh is innervated by the posterior femoral cutaneous nerve (S1-S3), not the sciatic. This distinction can be the difference between two answer choices on a nerve localization question.

452page
Added

Klumpke Palsy

Klumpke palsy now includes +/- Horner syndrome if T1 root/sympathetic chain involved

2025

Klumpke palsy: lower trunk (C8-T1) injury causing hand intrinsic muscle weakness with claw hand deformity.

2026

Klumpke palsy: lower trunk (C8-T1) injury causing hand intrinsic muscle weakness with claw hand deformity. +/- Horner syndrome (miosis, ptosis, anhidrosis) if T1 root or adjacent sympathetic chain is involved.

Why it matters

T1 sympathetic fibers travel near the lower brachial plexus trunk. Birth trauma traction can disrupt them, producing ipsilateral Horner syndrome. This is a classic two-finding localization question on Step 1.

467page
Added

Osteoporosis USPSTF Screening

USPSTF one-time DEXA screening for females >=65 added

2026

USPSTF guideline: One-time screening with DEXA scan recommended for all females aged 65 and older. Younger postmenopausal women should be screened if risk factors present (low body weight, prior fracture, family history, smoking, excess alcohol). FRAX score can guide decision-making in women aged 50-64.

Why it matters

Preventive medicine screening thresholds are NBME favorites. The magic number is 65 for women. USPSTF has insufficient evidence for routine screening in men, though some guidelines suggest 70+.

471page
Rewritten

Osteosarcoma Epidemiology

Osteosarcoma changed from peak in males <20 to bimodal distribution including elderly/Paget

2025

Peak incidence in males <20 years old.

2026

Bimodal age distribution: primary peak in adolescence (10-20 years, associated with rapid bone growth at metaphyses of long bones) AND second peak in elderly (often secondary to Paget disease or prior radiation therapy).

Why it matters

Secondary osteosarcoma in elderly patients with Paget disease is a classic boards association. New-onset bone pain + rising ALP + lytic lesion in known pagetic bone = suspect malignant transformation.

472page
Added

RA Cardiovascular Risk

RA chronic inflammation leads to increased aortic stenosis and premature cardiovascular disease

2026

Chronic systemic inflammation in RA leads to increased risk of aortic stenosis and premature cardiovascular disease. RA patients have 1.5-2x increased cardiovascular mortality compared to general population. Mechanism: chronic TNF-alpha, IL-6, and CRP elevation accelerate atherosclerosis and promote valvular calcification.

Why it matters

Cardiovascular disease (not joint destruction) is the leading cause of death in RA patients. When a question asks about RA mortality or systemic complications beyond joints, CVD is the answer.

+12 more Musculoskeletal & Skin changes — mapped page by page inside the Vault usmlevault.com →

Neurology & Special Senses

First Aid pp. 502–562

36changes
21 added9 rewritten4 cut2 moved1 correction
523page
FA 2025 correction

Clinical Reflexes Table — Brachioradialis Reflex

Brachioradialis reflex now specifically C6 (separated from biceps C5-C6)

2025

Biceps reflex = C5, C6; Brachioradialis reflex = C5, C6.

2026

Biceps reflex = C5, C6. Brachioradialis reflex = C6 (specifically). Triceps reflex = C7.

Why it matters

Factual correction: brachioradialis was previously lumped with biceps at C5-C6 but is now designated specifically C6. A patient with isolated brachioradialis reflex loss localizes to C6, not C5. This changes the correct answer in radiculopathy questions.

511page
Rewritten

Basal Ganglia Direct and Indirect Pathways

Direct and Indirect pathway paragraphs completely rewritten

2025

Direct pathway: Cortex → striatum → GPi/SNr → thalamus → cortex. Indirect pathway: Cortex → striatum → GPe → STN → GPi/SNr → thalamus → cortex.

2026

Direct pathway (facilitates movement): Cortex → striatum (D1 receptors) → inhibits GPi/SNr → disinhibits thalamus → excites cortex → movement. Indirect pathway (inhibits movement): Cortex → striatum (D2 receptors) → inhibits GPe → disinhibits STN → excites GPi/SNr → inhibits thalamus → less cortical stimulation → reduced movement.

Why it matters

The rewrite makes the receptor-level mechanism explicit (D1 = direct, D2 = indirect). This is the exact framing NBME uses in Parkinson/Huntington vignettes — you must know which receptor loss drives which pathway change.

511page
Added

Basal Ganglia Clinical Relevance

Dopamine ↓/↑ correlation with disease states now explicit

2026

↓ Dopamine (Parkinson disease) → ↓ direct pathway activity, ↑ indirect pathway activity → ↑ inhibition of thalamus → ↓ movement (hypokinesia). ↑ Dopamine (Huntington disease, hemiballismus) → ↑ direct pathway, ↓ indirect pathway → ↓ thalamic inhibition → excessive involuntary movement (hyperkinesia).

Why it matters

This is the single highest-yield addition in CNS for 2026. It directly maps dopamine levels to pathway changes to clinical presentation — the exact logic chain NBME tests in basal ganglia questions.

522page
Added

Spinothalamic Tract

Functional distinction between anterior and lateral spinothalamic tracts now explicit

2026

Spinothalamic tract functional divisions: Anterior (ventral) spinothalamic tract = crude touch and pressure. Lateral spinothalamic tract = pain and temperature. Both decussate within 1–2 levels of entry at the anterior white commissure.

Why it matters

This distinction is now directly testable. A lesion affecting only the lateral tract spares crude touch — exactly the kind of dissociation NBME loves in spinal cord lesion vignettes.

523page
Added

Landmark Dermatomes

L5 and S1 dermatomes added with clinical correlations

2026

L5: dorsum of foot, great toe dorsiflexion (extensor hallucis longus), no reliable reflex. S1: lateral foot/sole, plantar flexion, Achilles (ankle jerk) reflex.

Why it matters

L5 vs S1 is the most commonly tested dermatome distinction in disc herniation vignettes. L5 = dorsum of foot + great toe extension + no reflex loss. S1 = lateral sole + plantar flexion + ankle jerk loss.

+31 more Neurology & Special Senses changes — mapped page by page inside the Vault usmlevault.com →
Still on the 2025 edition? Start with the 5 factual corrections — those answers changed. Read the corrections at usmlevault.com →

Psychiatry

First Aid pp. 570–590

17changes
12 added4 rewritten1 cut
572page
Added

Grief

Prolonged grief disorder added — new DSM-5-TR diagnosis with specific duration thresholds

2025

Normal bereavement involves sadness, crying, and preoccupation with the deceased that gradually resolves over time.

2026

Normal bereavement involves sadness, crying, and preoccupation with the deceased that gradually resolves over time. Prolonged grief disorder (DSM-5-TR): persistent intense grief >12 months in adults (>6 months in children), preoccupation with the deceased, and functional impairment disproportionate to cultural norms.

Why it matters

New DSM-5-TR diagnosis means new questions. The 12-month adult threshold and 6-month child threshold are the testable numbers. Distinguish from MDD (broader depressive symptoms) and adjustment disorder (max 6 months).

575page
Added

Bipolar I Manic Episode Criteria

Hospitalization or psychotic features override the 7-day duration requirement for mania

2025

Manic episode: distinct period of abnormally elevated, expansive, or irritable mood lasting at least 7 days (or any duration if hospitalization is required).

2026

Manic episode: distinct period of abnormally elevated, expansive, or irritable mood lasting at least 7 days. Exception: hospitalization OR psychotic features at any point qualifies as mania regardless of duration — do not require full 7 days if either is present.

Why it matters

Classic board trap: a 4-day manic episode with hospitalization. Wrong answer is Bipolar II or unspecified bipolar. Correct answer is Bipolar I because hospitalization overrides the duration requirement. This exception is now explicitly testable.

578page
Added

Somatic Symptom vs Illness Anxiety Disorder

Key distinction between somatic symptom disorder and illness anxiety disorder made explicit

2025

Somatic symptom disorder: one or more somatic symptoms with excessive thoughts, feelings, or behaviors related to the symptoms.

2026

Somatic symptom disorder: one or more prominent somatic symptoms with excessive thoughts, feelings, or behaviors. Illness anxiety disorder: minimal or NO somatic symptoms with excessive worry about having a serious disease. The single distinguishing feature is presence vs absence of prominent somatic symptoms.

Why it matters

The presence vs absence of somatic symptoms is the one-line distinction boards test. Somatic symptom disorder = real bothersome symptoms + disproportionate response. Illness anxiety disorder = no symptoms + fear of undetected disease.

580page
Rewritten

Antisocial Personality Disorder

Antisocial PD definition expanded — conduct disorder before age 15 now required

2025

Antisocial personality disorder: disregard for and violation of rights of others.

2026

Antisocial personality disorder: manipulative, impulsive, callous disregard for rights of others. Diagnosis requires evidence of conduct disorder before age 15. Must be ≥18 for diagnosis. Conduct disorder history differentiates from narcissistic PD (which shares grandiosity/exploitation but lacks childhood behavioral pattern).

Why it matters

The conduct disorder requirement before age 15 is now explicitly testable. If a vignette describes antisocial behavior but NO childhood conduct problems, the answer may be narcissistic PD instead. Age requirements: conduct disorder <15, ASPD diagnosis ≥18.

583page
Added

ADHD Adult Presentation

Adult ADHD presentation added — predominantly inattentive, less hyperactivity

2025

ADHD: inattention, hyperactivity, impulsivity beginning before age 12.

2026

ADHD: inattention, hyperactivity, impulsivity beginning before age 12. Adult presentation: predominantly inattentive symptoms; hyperactivity becomes less prominent with age. Presents with time management difficulties, disorganization, executive dysfunction. Often diagnosed later (especially in women) because hyperactivity — the most visible childhood symptom — fades.

Why it matters

Adult ADHD is increasingly tested. The classic board trap is misdiagnosing it as GAD or MDD. Look for: childhood history of inattention + adult executive dysfunction + minimal hyperactivity + no mood symptoms. Women are disproportionately underdiagnosed.

+12 more Psychiatry changes — mapped page by page inside the Vault usmlevault.com →

Renal

First Aid pp. 598–626

9changes
5 added4 rewritten
598page
Added

Renal Tubular Acidosis Type 1 Treatment

Treatment for Type 1 (distal) RTA now specified: sodium citrate or sodium bicarbonate

2026

Treatment of Type 1 (distal) RTA: sodium citrate or sodium bicarbonate. Corrects metabolic acidosis and reduces complications (nephrocalcinosis, kidney stones).

Why it matters

RTA treatment was previously untestable because FA never listed it. Now Type 1 RTA treatment is fair game — expect a vignette with hypokalemia + urine pH > 5.5 + nephrocalcinosis asking for the next step in management.

598page
Added

Renal Tubular Acidosis Type 2 Treatment

Treatment for Type 2 (proximal) RTA now specified: sodium bicarbonate

2026

Treatment of Type 2 (proximal) RTA: sodium bicarbonate. Large doses may be required because supplemented bicarbonate is poorly reabsorbed and lost in urine.

Why it matters

The distinction between Type 1 (citrate OR bicarb) and Type 2 (bicarb only, high doses needed) is now a testable comparison. NBME loves asking why Type 2 requires higher doses — the answer is impaired proximal reabsorption.

598page
Added

Renal Tubular Acidosis Type 4 Mechanism

Type 4 RTA mechanism clarified: hyperkalemia decreases ammoniagenesis

2026

Type 4 RTA: hyperkalemia causes decreased ammoniagenesis in the proximal tubule, reducing NH3/NH4+ available for distal H+ buffering. This impairs net acid excretion despite intact distal H+ secretion (urine pH < 5.5).

Why it matters

This fills the mechanistic gap for Type 4 RTA. Previously students memorized hyperkalemia + low urine pH without understanding why. Now the two-step logic is testable: hyperkalemia inhibits NH3 production, which reduces acid buffering capacity.

617page
Rewritten

Minimal Change Disease EM Findings

Foot process effacement description broadened from NSs to glomerulopathies with variable degrees

2025

Effacement of foot processes on EM (Fused in most other NSs)

2026

Effacement of foot processes on EM (fused with variable degrees in other glomerulopathies)

Why it matters

The old wording implied uniform fusion across all nephrotic syndromes. Updated language clarifies two things: (1) fusion varies by disease severity and (2) it occurs in glomerulopathies broadly, not just nephrotic-range diseases.

626page
Rewritten

Loop Diuretics Calcium Handling

Added clinical exception: loops used therapeutically in hypercalcemia to lower serum calcium

2025

Loops Lose Ca2+

2026

Loops Lose Ca2+ (except in hypercalcemia: loops are used clinically to lower calcium)

Why it matters

Same pharmacologic property is both adverse effect AND therapeutic indication depending on context. NBME can now present a hypercalcemia case where loop diuretics are the correct answer — students must not dismiss loops just because they memorized it as a side effect.

+4 more Renal changes — mapped page by page inside the Vault usmlevault.com →

Reproductive

First Aid pp. 631–676

18changes
8 added4 rewritten6 moved
631page
Added

Neural Crest Cells

S100 immunohistochemical marker added to neural crest cells

2026

Neural crest cells are now marked as S100 positive. S100 is a calcium-binding protein used as an immunohistochemical marker for neural crest derivatives including schwannomas, neurofibromas, melanomas, and Langerhans cell histiocytosis.

Why it matters

S100 is a board-favorite IHC marker. Knowing neural crest = S100+ lets you identify schwannomas, melanomas, and neurofibromas in pathology vignettes that give you immunostaining results.

652page
Rewritten

Progesterone

Progesterone content updated with new information on page 652

2025

Progesterone content as previously presented on page 648.

2026

Progesterone content has been updated and relocated to page 652 with revised information reflecting current FA 2026 presentation.

Why it matters

Progesterone's page move came with content updates. Review the new page 652 layout to ensure your notes match the current edition's organization.

654page
Added

GnRH Pulsatility

New topic — GnRH pulsatility: pulsatile vs continuous administration

2026

GnRH pulsatility is a new FA 2026 topic. Pulsatile GnRH stimulates LH and FSH release (physiologic mechanism). Continuous GnRH (or GnRH agonist) administration causes initial stimulation (flare) followed by downregulation of GnRH receptors, resulting in LH/FSH suppression. Therapeutic applications of continuous GnRH agonists: precocious puberty, prostate cancer, endometriosis.

Why it matters

This is one of the most tested pharmacology concepts on Step 1. Understanding why a GnRH agonist (leuprolide) paradoxically suppresses gonadotropins when given continuously is essential for every reproductive and oncology vignette.

675page
Added

Progestin Safety in Breastfeeding

Progestins safe in breastfeeding and estrogen contraindications

2026

Compared to combined oral contraceptives, progestin-only pills are safe in breastfeeding women and those with estrogen contraindications (DVT history, migraines with aura, smokers >35 years old). Progestins do not increase thromboembolism risk and do not suppress lactation.

Why it matters

This is a clinical decision-making question. When a vignette gives you a breastfeeding woman or someone with DVT history asking about contraception, progestin-only is the answer — not combined OCPs.

676page
Added

Anabolic Androgenic Steroids

New topic — anabolic androgenic steroids and their side effects

2026

Anabolic androgenic steroids are testosterone derivatives used to increase muscle mass. Side effects include: testicular atrophy (due to HPG axis suppression), gynecomastia (peripheral aromatization of excess testosterone to estrogen), virilization in women, hepatotoxicity, dyslipidemia (decreased HDL, increased LDL), and aggression.

Why it matters

This is a classic clinical vignette: muscular man with infertility, testicular atrophy, and gynecomastia. The mechanism is HPG axis suppression from exogenous testosterone — connecting directly to the GnRH pulsatility concept.

+13 more Reproductive changes — mapped page by page inside the Vault usmlevault.com →

Respiratory

First Aid pp. 684–706

26changes
13 added5 rewritten1 cut7 moved
684page
Added

Pulmonary Circulation Hypoxic Vasoconstriction

Hypoxic vasoconstriction mechanism added with systemic contrast

2026

Pulmonary circulation: ↓ alveolar PO2 → pulmonary vasoconstriction (redirects blood to better-ventilated areas). This is the OPPOSITE of systemic circulation, where ↓ tissue PO2 → vasodilation to increase local oxygen delivery.

Why it matters

This is one of the highest-yield pulmonary physiology distinctions. Expect a vignette asking why a patient with lobar pneumonia isn't more hypoxic — the answer is hypoxic pulmonary vasoconstriction redirecting blood away from the consolidated lobe.

688page
Added

Methemoglobin

Fe3+ allosteric effect on remaining Fe2+ heme groups now explicit

2026

Methemoglobin: Fe3+ cannot bind O2, AND Fe3+ increases O2 affinity of remaining Fe2+ heme groups (O2 held tightly, cannot be released to tissues). This explains the LEFT shift on oxyhemoglobin dissociation curve + functional anemia despite normal total hemoglobin.

Why it matters

The dual mechanism is now testable: Fe3+ both reduces O2 capacity AND left-shifts the curve via allosteric effects on Fe2+ hemes. A vignette with normal PaO2 + cyanosis + chocolate-colored blood = methemoglobinemia.

694page
Added

Restrictive Diseases: CTD-ILD

Connective tissue diseases added as cause of ILD

2026

Connective tissue disease (RA, scleroderma, polymyositis/dermatomyositis) added as cause of interstitial lung disease. Scleroderma-ILD (NSIP pattern) is the most tested CTD-ILD association; anti-Scl-70 correlates with diffuse disease + ILD.

Why it matters

CTD-ILD is now explicitly listed. Scleroderma + ILD + anti-Scl-70 is the most tested pairing. Also know: RA = UIP pattern; polymyositis = anti-Jo-1 antibody associated with ILD.

706page
Added

COPD Triple Therapy

New topic: LAMA + LABA + ICS combination for moderate-severe COPD

2026

COPD triple therapy: LAMA + LABA + ICS combination. Indicated for moderate-severe COPD with frequent exacerbations despite dual bronchodilator therapy, especially with eosinophils ≥300 cells/μL. LAMA (tiotropium) blocks M3 → bronchodilation; LABA (formoterol) stimulates β2 → bronchodilation; ICS suppresses eosinophilic airway inflammation → reduces exacerbations.

Why it matters

Triple therapy is a new addition. The key testable distinction: ICS is added for anti-inflammatory effect (not bronchodilation). Eosinophil count ≥300 is the trigger for adding ICS to dual bronchodilator therapy.

706page
Added

Sotatercept for PAH

Sotatercept — activin receptor ligand trap for PAH

2026

Sotatercept: activin receptor ligand trap (fusion protein/decoy receptor). Binds activin ligands extracellularly → reduces TGF-β superfamily signaling → ↓ pulmonary vascular smooth muscle proliferation and remodeling → ↓ pulmonary vascular resistance. Used in pulmonary arterial hypertension (PAH) as add-on therapy.

Why it matters

Brand-new drug mechanism. The key distinction: sotatercept traps ligands EXTRACELLULARLY (decoy receptor), not intracellular kinase inhibition. Expect a mechanism-of-action question distinguishing it from ERAs and PDE-5 inhibitors.

+21 more Respiratory changes — mapped page by page inside the Vault usmlevault.com →